Gamma Delta CAR T-Cell Therapy Granted Fast Track Designation

The FDA granted Fast Track Designation to Adicet Bio’s ADI-001, an investigational therapy targeting CD20 for the potential treatment of relapsed or refractory B-cell NHL.

ADI-001 is an allogeneic gamma delta CAR T-cell therapy. According to the manufacturer, “Gamma delta T cells perform their tumor killing function in a major histocompatibility-independent manner and thus can be used in an allogeneic setting without the risk of causing graft-versus-host disease.”

If successful, this therapy could allow for generation of cell banks that could be used to treat many patients, allowing for “off-the-shelf” availability.

It is currently being evaluated in an ongoing dose-escalation, phase I study evaluating safety and tolerability.

Source: Adicet press release, April 2022